The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
Open accessAbstract
BACKGROUND: The incidence of hematologic cancers increases with age. These cancers are associated with recurrent somatic mutations in specific genes. We hypothesized that such mutations would be detectable in the blood of some persons who are not known to have hematologic disorders. METHODS: We analyzed whole-exome sequencing data from DNA in the peripheral-blood cells of 17,182 persons who were unselected for hematologic phenotypes. We looked for somatic mutations by identifying previously characterized single-nucleotide variants and small insertions or deletions in 160 genes that are recurrently mutated in hematologic cancers. The presence of mutations was analyzed for an association with hematologic phenotypes, survival, and cardiovascular events. RESULTS: Detectable somatic mutations were rare in persons younger than 40 years of age but rose appreciably in frequency with age. Among persons 70 to 79 years of age, 80 to 89 years of age, and 90 to 108 years of age, these clonal mutations were observed in 9.5% (219 of 2300 persons), 11.7% (37 of 317), and 18.4% (19 of 103), respectively. The majority of the variants occurred in three genes: DNMT3A, TET2, and ASXL1. The presence of a somatic mutation was associated with an increase in the risk of hematologic cancer (hazard ratio, 11.1; 95% confidence interval [CI], 3.9 to 32.6), an increase in all-cause mortality (hazard ratio, 1.4; 95% CI, 1.1 to 1.8), and increases in the risks of incident coronary heart disease (hazard ratio, 2.0; 95% CI, 1.2 to 3.4) and ischemic stroke (hazard ratio, 2.6; 95% CI, 1.4 to 4.8). CONCLUSIONS: Age-related clonal hematopoiesis is a common condition that is associated with increases in the risk of hematologic cancer and in all-cause mortality, with the latter possibly due to an increased risk of cardiovascular disease. (Funded by the National Institutes of Health and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Mutations in DNMT3A and TET2 account for over 90% of CH cases2,6”
From TET2-mutant myeloid cells mitigate Alzheimer’s disease progression via CNS infiltration and enhanced phagocytosis in mice (2025) · cites this paper as [2]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CHIP has emerged as a clinically relevant state associated with increased all-cause mortality and a broad spectrum of non-malignant diseases, most prominently atherosclerotic cardiovascular disease and stroke [1,4,5].”
From Clonal Hematopoiesis of Indeterminate Potential as an Emerging Interdisciplinary Risk Factor in Alzheimer’s Disease: Current Evidence and Future Directions (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CHIP carriers have an about 13-fold increased risk of developing myeloid hematological malignancies and an increased risk of all-cause mortality, largely due to cardiovascular disease and stroke.1, 2, 3, 4”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CHIP carriers have an about 13-fold increased risk of developing myeloid hematological malignancies and an increased risk of all-cause mortality, largely due to cardiovascular disease and stroke.1, 2, 3, 4”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, progression to hematological malignancies depends on the type and complexity of mutations in CHIP.2,5,6”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [2]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Loss-of-function heterozygous mutations in epigenetic regulators DNMT3A (cytosine methyltransferase) and TET2 (methylcytosine dioxygenase) are the most frequently detected mutations in CHIP, accounting for about 50% to 60% and 10% to 30% of mutations found in CHIP carriers, respectively.1, 2, 3,7,8”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Loss-of-function heterozygous mutations in epigenetic regulators DNMT3A (cytosine methyltransferase) and TET2 (methylcytosine dioxygenase) are the most frequently detected mutations in CHIP, accounting for about 50% to 60% and 10% to 30% of mutations found in CHIP carriers, respectively.1, 2, 3,7,8”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“More important, advanced age is the best predictor of CHIP, with a 5.6% or 18.4% prevalence in the sixth or ninth decade of life, respectively.2”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“are predicted to have high expansion rates (10% increase in mean VAF per year1, 2, 3,7)”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Clone size, which is approximated by the variant allele fraction (VAF), has previously been shown to be an important predictor of risk for blood cancer1,17 and cardiovascular outcomes8,9.”
From Clonal hematopoiesis is associated with protection from Alzheimer’s disease (2023) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Despite its hematologically silent nature, CH has been associated with increased mortality and morbidity [1,32].”
From Clonal hematopoiesis and inflammation – the perpetual cycle (2023) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“although increased red cell distribution width (RDW) has been reported (Jaiswal et al., 2014).”
From Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFNγ signaling (2021) · cites this paper as Jaiswal et al., 2014
The cited source says what the claim attributes to it.
In the citing paper
“This state of abnormal HSC expansion without overt hematologic disease is known as clonal hematopoiesis (CH), and is associated with increased risk of cardiovascular events and blood cancers (3)(4)(5).”
From Txnip Enhances Fitness of Dnmt3a -Mutant Hematopoietic Stem Cells via p21 (2022) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Instead, the discovery of widespread clonal expansions in ageing human tissues19,50–52 raises the possibility that some somatic mutations contribute to ageing by driving clonal expansions of functionally altered cells at a cost to the organism49,53,54.”
From Somatic mutation rates scale with lifespan across mammals (2022) · cites this paper as [50]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Methods adhered to published guidelines 77 .”
From Clonal hematopoiesis-associated motoric deficits caused by monocyte-derived microglia accumulating in aging mice (2025) · cites this paper as [77]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The isolated effects of individual inflammatory cytokines, including type 1 interferons (IFNa/b) 1-3 , type 2 IFN (IFNg) 4-6 , TNFa 7,8 , and IL-1 9-11 , have been well-documented in mouse hematopoietic development.”
From Type 1 interferon perturbates clonal competition by reshaping human blood development (2026) · cites this paper as [2]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Interestingly, while IFNa alters mouse HSC marker Sca-1 2 (rendering difficult the quantification of progenitor cell frequency changes by flow cytometric assessment in mice), IFNa did not alter CD90 expression after treatment in the HSPCs ( Fig. 2e, Supplementary Fig. 3c ).”
From Type 1 interferon perturbates clonal competition by reshaping human blood development (2026) · cites this paper as [2]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previously, induction of IFNa in mice have yielded mixed results demonstrating either an upregulation 2 or downregulation 53 of TNFa.”
From Type 1 interferon perturbates clonal competition by reshaping human blood development (2026) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“clonal hematopoiesis is a frequent event in elderly people.”
From Aging of hematopoietic stem cells (2018) · cites this paper as [76]
In the citing paper
“Epigenetic genes that are relatively frequently affected in these conditions include DNMT3A, EZH2, TET2, and SETDB1.”
From Aging of hematopoietic stem cells (2018) · cites this paper as [76]
In the citing paper
“The phenomenon also appears to be counterintuitively well tolerated, where HSCs containing oncogenic mutations can overtake most of the hematopoietic system without transforming into leukemia (Jaiswal et al., 2014).”
From Unraveling Hematopoiesis through the Lens of Genomics (2020) · cites this paper as Jaiswal et al., 2014
In the citing paper
“The size of these mutant clones was massive; in one study, a median of ~18% of blood cells carried the mutations 28.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“For example, CHIP has been reported to be more common in older men 28 and smokers 27 and less common in Hispanics 28, although these associations are all relatively modest.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“Indeed, in population-based cohorts that underwent exome sequencing, the presence of CHIP was associated with ~10-fold increased relative risk of these malignancies over several years of follow-up 27,28.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“CHIP itself does not denote a malignancy, nor is it associated with clinically significant alterations in blood counts 28,63.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“In an initial study, this risk could not be explained by cancer deaths but was instead related to increased cardiovascular mortality 28.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“In one study, 4% of CHIP carriers developed a blood cancer over the subsequent 8 years, corresponding to ~0.5% of CHIP cases converting to malignancy per year 28.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“Several studies have found that CHIP is associated with a 30–40% increased mortality risk 27,28,37.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“Myeloid malignancies were most common, although some people with CHIP did develop lymphoid cancers 27,28.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“Indeed, some individuals with clonal hematopoiesis have virtually all of their blood cells arising from a single mutated HSC 28.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“CHIP has been found to be associated with a 30% increase in the likelihood of having type 2 diabetes (T2D) 28.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“Studies of serial samples have shown that the trajectory of a clone can vary between people.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“Some people have clones that remain stagnant in size for many years, whereas other people have clones that show steady growth 28,33.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“These findings are supported by recent findings demonstrating a causal link between mutations in HSPCs in the context of clonal hematopoiesis with indeterminate origin and altered transcriptional output of macrophages, which affect the vascular wall and contributes to atherosclerosis.83,84”
From Inflammatory bone marrow microenvironment (2019) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Inflammation in atherosclerosis
Libby, P. (2002) · Nature · doi:10.1038/nature01323 · Cited by 8,315
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D. B., Sougnez, C. L., Gabriel, S., Meyerson, M. M., Lander, E. S., & Getz, G. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,965
Self-citationInflammation and insulin resistance
Shoelson, S. E. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29069 · Cited by 4,769
Inflammation in Atherosclerosis
Libby, P. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.179705 · Cited by 3,796
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Self-citationMacrophages, inflammation, and insulin resistance
Olefsky, J. M., & Glass, C. K. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135846 · Cited by 2,733
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Cited by
Sorted by citations
Items 801–900 of 1,023
TET2 as a tumor suppressor and therapeutic target in T-cell acute lymphoblastic leukemia
Bensberg, M., Rundquist, O., Selimović-Pašić, A., Lagerwall, C., Benson, M., Gustafsson, M., Vogt, H., Lentini, A., & Nestor, C. E. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2110758118 · Cited by 70
Longitudinal profiling of clonal hematopoiesis provides insight into clonal dynamics
Uddin, M. M., Zhou, Y., Bick, A. G., Burugula, B. B., Jaiswal, S., Desai, P. M., Honigberg, M. C., Love, S.-A. M., Barac, A., Hayden, K. M., et al. (2022) · Immunity & Ageing · doi:10.1186/s12979-022-00278-9 · Cited by 73
Self-citationMas‐Peiró, S., Abplanalp, W. T., Rasper, T., Berkowitsch, A., Leistner, D. M., Dimmeler, S., & Zeiher, A. M. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad093 · Cited by 71
Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma
Lasseter, K. D., Nassar, A. H., Hamieh, L., Berchuck, J. E., Nuzzo, P. V., Korthauer, K. D., Shinagare, A. B., Ogórek, B., McKay, R. R., Thorner, A. R., et al. (2020) · Genetics in Medicine · doi:10.1038/s41436-020-0801-x · Cited by 72
van Beek, H., Kirkwood, T. B. L., & Bassingthwaighte, J. B. (2016) · Interface Focus · doi:10.1098/rsfs.2015.0079 · Cited by 77
Immune Mechanisms in Myelodysplastic Syndrome
Glenthøj, A. B., Ørskov, A. D., Hansen, J., Hadrup, S. R., O'Connell, C. L., & Grønbæk, K. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17060944 · Cited by 69
Kotyla, P. J., Engelmann, M., Giemza-Stokłosa, J., Wnuk, B. R., & Islam, M. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052449 · Cited by 70
Genetics and epidemiology of mutational barcode-defined clonal hematopoiesis
Stacey, S., Zink, F., Halldorsson, G. H., Stefánsdóttir, L., Gudjonsson, S. A., Einarsson, G., Hjörleifsson, G., Eiriksdottir, T., Helgadóttir, A., Björnsdóttir, G., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01555-z · Cited by 71
Malignant JAK-signaling: at the interface of inflammation and malignant transformation
Perner, F., Pahl, H. L., Zeiser, R., & Heidel, F. H. (2025) · Leukemia · doi:10.1038/s41375-025-02569-8 · Cited by 71
Genomics of Myeloproliferative Neoplasms
Zoi, K., & Cross, N. C. P. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.7968 · Cited by 73
Perdomo, S. P., Avogbe, P. H., Foll, M., Abedi‐Ardekani, B., Facciolla, V. L., Anantharaman, D., Chopard, P., Calvez‐Kelm, F. L., Vilensky, M., Polesel, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20004 · Cited by 71
Consequences of mutant TET2 on clonality and subclonal hierarchy
Hirsch, C. M., Nazha, A., Kneen, K. E., Abazeed, M. E., Meggendorfer, M., Przychodzen, B. P., Nadarajah, N., Ademà, V., Nagata, Y., Goyal, A., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0150-9 · Cited by 71
Clinical implications of molecular markers in acute myeloid leukemia
Käyser, S., & Levis, M. J. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13172 · Cited by 70
Fei, D. L., Zhen, T., Durham, B. H., Ferrarone, J. R., Zhang, T., Garrett, L. J., Yoshimi, A., Abdel-Wahab, O. I., Bradley, R. K., Liu, P., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1812669115 · Cited by 72
Cell‐free tumour DNA testing for early detection of cancer – a potential future tool
Barbany, G., Arthur, C., Liedén, A., Nordenskjöld, M., Rosenquist, R., Tesi, B., Wallander, K., & Tham, E. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12897 · Cited by 73
Clonal Hematopoiesis and Blood-Cancer Risk
Genovese, G., Jaiswal, S., Ebert, B. L., & McCarroll, S. A. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1500684 · Cited by 70
Self-citationInflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis
Zioni, N., Bercovich, A. A., Chapal-Ilani, N., Bacharach, T., Rappoport, N., Solomon, A., Avraham, R., Kopitman, E., Porat, Z., Sacma, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36906-1 · Cited by 67
Chaudry, S. F., & Chevassut, T. J. T. (2017) · BioMed Research International · doi:10.1155/2017/5473197 · Cited by 69
Evolving Significance of Tumor-Normal Sequencing in Cancer Care
Mandelker, D. L., & Ceyhan‐Birsoy, O. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.11.006 · Cited by 67
Clonal Hematopoiesis: A New Step Linking Inflammation to Heart Failure
Yura, Y., Sano, S., & Walsh, K. X. (2020) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2019.08.006 · Cited by 69
Nucleophosmin 1 Mutations in Acute Myeloid Leukemia
Zarka, J. G., Short, N. J., Kanagal‐Shamanna, R., & Issa, G. C. (2020) · Genes · doi:10.3390/genes11060649 · Cited by 68
Kirtonia, A., Pandya, G., Sethi, G., Pandey, A. K., Das, B. C., & Garg, M. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01944-5 · Cited by 68
Synonymous mutations reveal genome-wide levels of positive selection in healthy tissues
Poon, G. Y. P., Watson, C. J., Fisher, D. S., & Blundell, J. R. (2021) · Nature Genetics · doi:10.1038/s41588-021-00957-1 · Cited by 67
Bick, A. G., Popadin, K., Thorball, C. W., Uddin, M. M., Zanni, M. V., Yu, B., Cavassini, M., Rauch, A., Tarr, P., Schmid, P., et al. (2022) · Scientific Reports · doi:10.1038/s41598-021-04308-2 · Cited by 68
Hajishengallis, G., Li, X., Divaris, K., & Chavakis, T. (2022) · Periodontology 2000 · doi:10.1111/prd.12421 · Cited by 70
Cortés-López, M., Chamely, P., Hawkins, A. G., Stanley, R. F., Swett, A. D., Ganesan, S., Mouhieddine, T. H., Dai, X., Kluegel, L., Chen, C. Y., et al. (2023) · Cell stem cell · doi:10.1016/j.stem.2023.07.012 · Cited by 69
Self-citationDillon, L. W., Gui, G., Ravindra, N., Andrew, G. M., Mukherjee, D., Wong, Z. C., Huang, Y., Gerhold, J., Holman, M., D’Angelo, J., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.0985 · Cited by 67
Self-citationMetformin reduces the competitive advantage of Dnmt3aR878H HSPCs
Hosseini, M., Voisin, V., Chegini, A., Varesi, A., Cathelin, S., Ayyathan, D. M., Liu, A. C. H., Yang, Y., Wang, V. Y., Maher, A., et al. (2025) · Nature · doi:10.1038/s41586-025-08871-w · Cited by 70
Patterns of mutations in TP53 mutated AML
Welch, J. S. (2018) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2018.09.010 · Cited by 68
Genome Sequencing during a Patient’s Journey through Cancer
Nangalia, J., & Campbell, P. J. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1910138 · Cited by 66
Rinke, J., Chase, A., Cross, N. C. P., Hochhaus, A., & Ernst, T. (2020) · Cells · doi:10.3390/cells9071639 · Cited by 71
Clonal hematopoiesis in the inherited bone marrow failure syndromes
Tsai, F. D., & Lindsley, R. C. (2020) · Blood · doi:10.1182/blood.2019000990 · Cited by 69
Self-citationAlterations to DNMT3A in Hematologic Malignancies
Venugopal, K., Feng, Y., Shabashvili, D. E., & Guryanova, O. A. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-3033 · Cited by 70
Genome editing in cardiovascular diseases
Mani, I. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.021 · Cited by 66
Single-cell genomics in AML: extending the frontiers of AML research
Ediriwickrema, A., Gentles, A. J., & Majeti, R. (2022) · Blood · doi:10.1182/blood.2021014670 · Cited by 69
Biology and therapeutic targeting of molecular mechanisms in MPNs
How, J., Garcia, J. S., & Mullally, A. (2022) · Blood · doi:10.1182/blood.2022017416 · Cited by 75
NLRP3 and cancer: Pathogenesis and therapeutic opportunities
Tengesdal, I. W., Dinarello, C. A., & Marchetti, C. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108545 · Cited by 70
Jak2 V617F clonal hematopoiesis promotes arterial thrombosis via platelet activation and cross talk
Liu, W., Pircher, J., Schuermans, A., Ain, Q. U., Zhang, Z., Honigberg, M. C., Yalçınkaya, M., Nakao, T., Pournamadri, A., Xiao, T., et al. (2023) · Blood · doi:10.1182/blood.2023022260 · Cited by 68
Rando, T. A., Brunet, A., & Goodell, M. A. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.06.004 · Cited by 68
for the German-Austrian Acute Myeloid Leukemia Study Group (AMLSG), Gaidzik, V. I., Weber, D., Paschka, P., Kaumanns, A., Krieger, S., Corbacioglu, A., Krönke, J., Kapp‐Schwoerer, S., Kraemer, D. M., et al. (2017) · Leukemia · doi:10.1038/leu.2017.200 · Cited by 69
Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML
Valent, P., Kern, W., Hoermann, G., Feenstra, J. D. M., Sotlar, K., Pfeilstöcker, M., Germing, U., Sperr, W. R., Reiter, A., Wolf, D. G. F., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030789 · Cited by 68
Clonal Hematopoiesis and Its Impact on Human Health
Ahmad, H., Jahn, N., & Jaiswal, S. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-112347 · Cited by 66
Self-citationNagata, Y., Makishima, H., Kerr, C. M., Przychodzen, B. P., Aly, M. M., Goyal, A., Awada, H. K., Asad, M., Kuzmanovic, T., Suzuki, H., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13001-y · Cited by 69
Clonal hematopoiesis as a model for premalignant changes during aging
Steensma, D. P., & Ebert, B. L. (2019) · Experimental Hematology · doi:10.1016/j.exphem.2019.12.001 · Cited by 65
Self-citationTargeting Inflammation to Reduce Residual Cardiovascular Risk
Ajala, O. N., & Everett, B. M. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00883-3 · Cited by 65
Clonal hematopoiesis in sickle cell disease
Pincez, T., Lee, S., Ilboudo, Y., Preuss, M. H., D'Orengiani, A.-L. P. H. D., Bartolucci, P., Galactéros, F., Joly, P., Bauer, D. E., Loos, R. J. F., et al. (2021) · Blood · doi:10.1182/blood.2021011121 · Cited by 66
Self-citationStengel, A., Baer, C. R., Walter, W., Meggendorfer, M., Kern, W., Haferlach, T., & Haferlach, C. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004668 · Cited by 65
Chronic obstructive pulmonary disease and atherosclerosis: common mechanisms and novel therapeutics
Brassington, K., Selemidis, S., Bozinovski, S., & Vlahos, R. (2022) · Clinical Science · doi:10.1042/cs20210835 · Cited by 72
Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease
Chapman, M. S., Cull, A. H., Ciuculescu, M. F., Esrick, E. B., Mitchell, E., Jung, H., O’Neill, L., Roberts, K., Fabre, M. A., Williams, N., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02636-6 · Cited by 66
Li, B., Liu, J., Jia, Y., Wang, J., Xu, Z., Qin, T., Shi, Z., Song, Z., Peng, S., Huang, H., et al. (2017) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22510 · Cited by 66
Hoogeveen, R. M., Nahrendorf, M., Riksen, N. P., Netea, M. G., de Winther, M. P. J., Lutgens, E., Nordestgaard, B. G., Neidhart, M., Stroes, E. S. G., Catapano, A. L., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx581 · Cited by 65
The Role of Additional Sex Combs-Like Proteins in CancerPreprint
Micol, J., & Abdel-Wahab, O. I. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026526 · Cited by 65
Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?
Heuser, M. (2016) · Hematology · doi:10.1182/asheducation-2016.1.24 · Cited by 66
Recent advances in understanding clonal haematopoiesis in aplastic anaemia
Stanley, N. L., Olson, T. S., & Babushok, D. V. (2017) · British Journal of Haematology · doi:10.1111/bjh.14510 · Cited by 65
Midic, D., Rinke, J., Perner, F., Müller, V., Hinze, A., Pester, F., Landschulze, J., Ernst, J., Gruhn, B., Matziolis, G., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0869-y · Cited by 65
High prevalence of clonal hematopoiesis in the blood and bone marrow of healthy volunteers
Guermouche, H., Ravalet, N., Gallay, N., Deswarte, C., Foucault, A., Beaud, J., Rault, E., Saindoy, E., Lachot, S., Martignoles, J., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001582 · Cited by 65
Wouters, H. J. C. M., Mulder, R., van Zeventer, I. A., Schuringa, J. J., van der Klauw, M. M., van der Harst, P., Diepstra, A., Mulder, A. B., & Huls, G. A. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020003323 · Cited by 66
Ainciburu, M., Ezponda, T., Berastegui, N., Piérola, A. A., Vilas‐Zornoza, A., Martín‐Úriz, P. S., Alignani, D., Lamo-Espinosa, J. M., San-Julián, M., Jiménez, T., et al. (2023) · eLife · doi:10.7554/elife.79363 · Cited by 68
Li, Y., Berliocchi, L., Li, Z., & Rasmussen, L. J. (2023) · Aging Cell · doi:10.1111/acel.13942 · Cited by 66
Mapping genotypes to chromatin accessibility profiles in single cells
Izzo, F., Myers, R. M., Ganesan, S., Mekerishvili, L., Kottapalli, S., Prieto, T., Eton, E. O., Botella, T., Dunbar, A. J., Bowman, R. L., et al. (2024) · Nature · doi:10.1038/s41586-024-07388-y · Cited by 67
Biology and Clinical Relevance of Acute Myeloid Leukemia Stem Cells
Reinisch, A., Chan, S. M., Thomas, D., & Majeti, R. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.03.008 · Cited by 68
Russell, B. E., Johnston, J. J., Biesecker, L. G., Kramer, N., Pickart, A. M., Rhead, W. J., Tan, W., Brownstein, C. A., Clarkson, L. K., Dobson, A., et al. (2015) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.37131 · Cited by 64
The curious origins of angioimmunoblastic T-cell lymphoma
Cortés, J. R., & Palomero, T. (2016) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000261 · Cited by 65
Latchney, S. E., & Calvi, L. M. (2016) · Seminars in Hematology · doi:10.1053/j.seminhematol.2016.10.001 · Cited by 70
Clonal Hematopoiesis: Somatic Mutations in Blood Cells and Atherosclerosis
Natarajan, P., Jaiswal, S., & Kathiresan, S. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.118.001926 · Cited by 63
Self-citationRisk and timing of cardiovascular death among patients with myelodysplastic syndromes
Brunner, A. M., Blonquist, T. M., Hobbs, G. S., Amrein, P. C., Neuberg, D. S., Steensma, D. P., Abel, G. A., & Fathi, A. T. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017010165 · Cited by 63
Self-citationLeveraging premalignant biology for immune-based cancer prevention
Spira, A. E., Disis, M. L., Schiller, J. T., Vilar, E., Rebbeck, T. R., Bejar, R. L., Ideker, T., Arts, J., Yurgelun, M. B. B., Mesirov, J. P., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608077113 · Cited by 64
Preleukemia: one name, many meanings
Koeffler, H. P., & Leong, G. X. Y. (2016) · Leukemia · doi:10.1038/leu.2016.364 · Cited by 67
Clonal hematopoiesis in cancer
Park, S. J., & Bejar, R. L. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.02.001 · Cited by 66
Ghannam, J. Y., Xu, X., Marić, I., Dillon, L. W., Li, Y., Hsieh, M. M., Hourigan, C. S., & Fitzhugh, C. D. (2020) · Blood · doi:10.1182/blood.2019004001 · Cited by 64
Immune Mechanisms of Plaque Instability
Gerhardt, T., Haghikia, A., Stapmanns, P., & Leistner, D. M. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.797046 · Cited by 66
Clonal haematopoiesis is associated with higher mortality in patients with cardiogenic shock
Scolari, F. L., Abelson, S., Brahmbhatt, D. H., Medeiros, J. J. F., Fan, C. S., Fung, N. L., Mihajlovic, V., Anker, M. S., Otsuki, M., Lawler, P. R., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2588 · Cited by 66
Functional diversity of cardiac macrophages in health and disease
Yang, S. H., Penna, V. R., & Lavine, K. J. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01109-8 · Cited by 67
Time to repeal and replace response criteria for acute myeloid leukemia?
Bloomfield, C. D., Estey, E. H., Pleyer, L., Schuh, A. C., Stein, E. M., Tallman, M. S., & Wei, A. H. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.03.006 · Cited by 63
Link-Lenczowska, D., Pallisgaard, N., Cordua, S., Zawada, M., Czekalska, S., Krochmalczyk, D., Kanduła, Z., & Sacha, T. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3451-1 · Cited by 67
Discrete Changes in Glucose Metabolism Define Aging
Ravera, S., Podestà, M., Sabatini, F., Dagnino, M., Cilloni, D., Fiorini, S., Barla, A., & Frassoni, F. (2019) · Scientific Reports · doi:10.1038/s41598-019-46749-w · Cited by 63
Immune-Based Therapies in Acute Leukemia
Witkowski, M. T., Lasry, A., Carroll, W. L., & Aifantis, I. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.07.009 · Cited by 65
Gondek, L. P., & Dezern, A. E. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30211-x · Cited by 67
Sex-Specific Effects of the Nlrp3 Inflammasome on Atherogenesis in LDL Receptor-Deficient Mice
Chen, S., Markman, J. L., Shimada, K., Crother, T. R., Lane, M. E., Abolhesn, A., Shah, P. K., & Arditi, M. (2020) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2020.03.016 · Cited by 63
Tong, J., Sun, T., Ma, S., Zhao, Y., Ju, M., Gao, Y., Zhu, P., Tan, P., Fu, R., Zhang, A., et al. (2021) · Cell stem cell · doi:10.1016/j.stem.2021.01.018 · Cited by 68
Singhal, D., Wee, L. Y. A., Kutyna, M. M., Chhetri, R., Geoghegan, J., Schreiber, A. W., Feng, J., Wang, P. P.-S., Babic, M., Parker, W. T., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0479-8 · Cited by 62
Frequent somatic TET2 mutations in chronic NK-LGL leukemia with distinct patterns of cytopenias
Olson, T. L., Cheon, H., Xing, J. C., Olson, K. C., Paila, U., Hamele, C. E., Neelamraju, Y., Shemo, B. C., Schmachtenberg, M. W., Sundararaman, S. K., et al. (2021) · Blood · doi:10.1182/blood.2020005831 · Cited by 63
Obesity and Cardiovascular Disease: The Emerging Role of Inflammation
Khafagy, R. T. M., & Dash, S. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.768119 · Cited by 69
The Mechanism of Stem Cell Aging
Mi, L., Hu, J., Li, N., Gao, J., Huo, R., Peng, X., Zhang, N., Liu, Y., Zhao, H., Liu, R., et al. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-021-10317-5 · Cited by 64
Interleukin-1 (IL-1) and the inflammasome in cancer
Prêtre, V., Papadopoulos, D., Regard, J. B., Pelletier, M. R., & Woo, J. (2022) · Cytokine · doi:10.1016/j.cyto.2022.155850 · Cited by 66
Cardio-Oncology: A Myriad of Relationships Between Cardiovascular Disease and Cancer
Wang, Y., Wang, Y., Han, X., Sun, J. H., Li, C., Adhikari, B. K., Zhang, J., Miao, X., & Chen, Z. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.727487 · Cited by 63
Risk prediction for clonal cytopenia: multicenter real-world evidence
Xie, Z., Komrokji, R. S., Al‐Ali, N., Regelson, A., Geyer, S. M., Patel, A. A., Saygin, C., Zeidan, A. M., Bewersdorf, J. P., Mendez, L., et al. (2024) · Blood · doi:10.1182/blood.2024024756 · Cited by 63
JAK2-mutant clonal hematopoiesis is associated with venous thromboembolism
Zon, R. L., Sekar, A., Clapham, K. R., Oren, O., Niroula, A., Bick, A. G., Gibson, C. J., Griffin, G. K., Uddin, M. M., Neuberg, D. S., et al. (2024) · Blood · doi:10.1182/blood.2024024187 · Cited by 67
Self-citationde Andrade, K. C., Mirabello, L. J., Stewart, D. R., Karlins, E., Koster, R., Wang, M., Gapstur, S. M., Gaudet, M. M., Freedman, N. D., Landi, M. T., et al. (2017) · Human Mutation · doi:10.1002/humu.23320 · Cited by 63
RNA-binding proteins in hematopoiesis and hematological malignancy
Hodson, D. J., Screen, M., & Turner, M. (2019) · Blood · doi:10.1182/blood-2018-10-839985 · Cited by 64
Age-related clonal haemopoiesis is associated with increased epigenetic age
Robertson, N., Hillary, R. F., McCartney, D. L., Terradas-Terradas, M., Higham, J., Sproul, D., Deary, I. J., Kirschner, K., Marioni, R. E., & Chandra, T. (2019) · Current Biology · doi:10.1016/j.cub.2019.07.011 · Cited by 63
Dasari, A. N., Grothey, A. F., & Kopetz, S. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9032 · Cited by 64
The Molecular Genetics of Myeloproliferative NeoplasmsPreprint
Marneth, A. E., & Mullally, A. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a034876 · Cited by 65
Clonal Hematopoiesis and Atherosclerosis
Jaiswal, S., Natarajan, P., & Ebert, B. L. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1710381 · Cited by 64
Self-citationEvaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer
Taavitsainen, S., Annala, M., Ledet, E. M., Beja, K., Miller, P. J., Moses, M. W., Nykter, M., Chi, K. N., Sartor, O. A., & Wyatt, A. W. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00014 · Cited by 64
The epigenetically-encoded memory of the innate immune system
Sun, S., & Barreiro, L. B. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.02.002 · Cited by 61
Clonal Hematopoiesis Before, During, and After Human Spaceflight
Mencia-Trinchant, N., MacKay, M. J., Chin, C. R., Afshinnekoo, E., Foox, J., Meydan, C., Butler, D., Mozsary, C., Vernice, N. A., Darby, C. A., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108458 · Cited by 62
The role of vitamin C in epigenetic cancer therapy
Mikkelsen, S. U., Gillberg, L., Lykkesfeldt, J., & Grønbæk, K. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.03.017 · Cited by 62
Somatic mutations in lymphocytes in patients with immune-mediated aplastic anemia
Lundgren, S., Keränen, M. A. I., Kankainen, M., Huuhtanen, J., Walldin, G., Kerr, C. M., Clemente, M. J., Ebeling, F. T., Rajala, H. L. M., Brück, O. E., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01231-3 · Cited by 63
Clinico-genetic findings in 509 frontotemporal dementia patients
Wagner, M., Lorenz, G., Volk, A. E., Brunet, T., Edbauer, D., Berutti, R., Zhao, C., Anderl‐Straub, S., Bertram, L., Danek, A., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01271-2 · Cited by 59
Metadata
- Authors
- Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., Higgins, J. M., Moltchanov, V., Kuo, F. C., Kluk, M. J., Henderson, B., Kinnunen, L., Koistinen, H. A., Ladenvall, C., Getz, G., Correa, A., Banahan, B. F., Gabriel, S., Kathiresan, S., Stringham, H. M., McCarthy, M. I., Boehnke, M., Tuomilehto, J., Haiman, C., Groop, L., Atzmon, G., Wilson, J. G., Neuberg, D., Altshuler, D., & Ebert, B. L.
- Affiliations
- Brigham and Women's Hospital (US)
- Broad Institute (US)
- University of Helsinki (FI)
- University of Southern California (US)
- Helsinki University Hospital (FI)
- Lund University (SE)
- University of Mississippi Medical Center (US)
- University of Michigan (US)
- Centre for Human Genetics (GB)
- Universität für Weiterbildung Krems (AT)
- Albert Einstein College of Medicine (US)
- Harvard University (US)
- ORCID
- Jaiswal, Siddhartha
- Fontanillas, Pierre
- Flannick, Jason
- Manning, Alisa
- Mar, Brenton G.
- Lindsley, R. Coleman
- Mermel, Craig H.
- Chavez, Alejandro
- Higgins, John M.
- Kuo, Frank C.
- Kluk, Michael J.
- Kinnunen, Leena
- Koistinen, Heikki A.
- Ladenvall, Claes
- Getz, Gad
- Correa, Adolfo
- Banahan, Benjamin F.
- Gabriel, Stacey
- Kathiresan, Sekar
- Stringham, Heather M.
- McCarthy, Mark I.
- Boehnke, Michael
- Tuomilehto, Jaakko
- Groop, Leif
- Atzmon, Gil
- Wilson, James G.
- Neuberg, Donna
- Altshuler, David
- Ebert, Benjamin L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-12-25
- Volume
- 371
- Issue
- 26
- Pages
- 2488-2498
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4306669
- OpenAlex
- W2149858388
- Cited by
- 4,841
- References
- 48
- Citations by year
- 2026: 423 · 2025: 446 · 2024: 494 · 2023: 521 · 2022: 536 · 2021: 520 · 2020: 454 · 2019: 387 · 2018: 356 · 2017: 301 · 2016: 237 · 2015: 151 · 2014: 6
- FWCI
- 164.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Lund University Publications (Lund University) (submittedVersion, other-oa)
- STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
- Funders
- Wellcome Trust (090367, 085475, 098381, 090532, 083948)
- National Institutes of Health (5rc2dk088389-02)
- National Institute on Aging (R01AG042188, P01AG021654, P30AG038072)
- National Heart, Lung, and Blood Institute (R01HL082945, T32HL066987)
- National Human Genome Research Institute (U54HG003067)
- National Cancer Institute (T32CA009216, T32CA009172, P01CA066996)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK085526, U01DK085584, DP2DK098087, U01DK085501, U01DK085524, RC2-DK088389, U01DK085545, DK088389, P30DK020572)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
- Keywords
- age-related clonal hematopoiesis, somatic mutations, all-cause mortality, coronary artery disease, ischemic stroke, cardiovascular disease, DNMT3A, TET2, ASXL1, peripheral blood, aging
- MeSH terms
- Adult, Age Factors, Aged, Aged, 80 and over, Blood, Cell Transformation, Neoplastic, Clone Cells, DNA Mutational Analysis, Hematopoiesis, Hematopoietic Stem Cells, Humans, Middle Aged, Mutation, Risk Factors, Hematologic Neoplasms, Young Adult, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
